Dendreon To Host Conference Call On March 3 To Announce Fourth Quarter And Full Year 2013 Financial Results

Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Monday, March 3, 2014 at 9:00 a.m. EST to review fourth quarter and full year 2013 financial results.

Access to the discussion may be obtained as follows:
Time:     9:00 a.m. EST / 6:00 a.m. PST
Date: March 3, 2014
Dial-in: 1-877-548-9590 (domestic) or +1-720-545-0037 (international)

 

Conference ID number: 57711925

Webcast:

www.dendreon.com (homepage and investor relations section)
 

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-855-859-2056 or +1-404-537-3406 for international callers; the conference ID number is 57711925. The replay will be available from 12:00 p.m. EST on Monday, March 3, 2014, until 11:59 p.m. EST on Sunday, March 9, 2014. In addition, the webcast will be archived for on-demand listening for 90 days at www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes